Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration
Active, not recruiting · Phase 2 · NCT01736592
Conditions: Stargardt's Disease
At a glance
- Research payments reported, 2025
- $42,252
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 27
About the trial
- Sponsor
- Sanofi
- Tested
- Long term follow up in all patients who received SAR422459 in previous study TDU13583 (drug)
- Dates
- Started 2012-12-14; completion 2033-08-29
- Results posted
- Not yet
Primary Objective: To evaluate the long-term safety and tolerability of SAR422459 in patients with Stargardt's Macular Degeneration. Secondary Objective: To assess: * Safety * Biological activity
From ClinicalTrials.gov, last updated 2026-08-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Genzyme Corporation reported $42,252 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.